Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Farmers Insurance
Harvard Business School
Boehringer Ingelheim
Cipla

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,417,148

« Back to Dashboard

Which drugs does patent 7,417,148 protect, and when does it expire?

Patent 7,417,148 protects BOSULIF and is included in one NDA.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 7,417,148
Title:4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Abstract: Compounds of the formula: ##STR00001## wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R.sup.1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R.sup.2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.
Inventor(s): Boschelli; Frank (New City, NY), Arndt; Kim T. (Towaco, NJ), Golas; Jennifer M. (Hewitt, NJ)
Assignee: Wyeth (Madison, NJ)
Application Number:10/980,097
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,417,148
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,417,148
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,417,148

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-001 Sep 4, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-003 Oct 27, 2017 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-002 Sep 4, 2012 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Chubb
UBS
Teva
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.